MedTrace Logo

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

NCT03748706 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2021-07-07

Study results available
· View outcomes & findings →

Summary

This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate Alzheimer's disease patients.

Conditions

  • Alzheimer Disease

Interventions

DRUG

PTI-125, 100 mg tablets

PTI-125, 100 mg tablets taken twice a day for 28 days

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Pain Therapeutics

    lead INDUSTRY

Principal Investigators

  • Lindsay Burns, PhD · Cassava Sciences, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-07
Primary Completion
2019-05-08
Completion
2019-05-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03748706 on ClinicalTrials.gov